在B细胞急性淋巴细胞白血病的印度患者中使用Inotuzumab Ozogamicin
Pronamee Borah1, Vivek Mohan1, Sachin Jain2
1Department of Hematology and Bone Marrow Transplant, Paras Health, Gurugram, India.
概括
伊诺图祖马布 (ozogamicin) 有效地诱导复发性耐火性B细胞急性淋巴细胞白血病的深度缓解. 这项研究表明,83%的患者实现了可测量的残留病负完全缓解,突出显示了它对印度患者的有用性.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 有限的数据存在于印度患者的伊诺图祖马布奥佐加米辛 (InO) 实用性复发性耐火性急性淋巴细胞白血病 (RR-ALL).
- 急性淋巴细胞白血病 (ALL) 仍然是一个重大挑战,特别是在其复发或耐火形式.
研究的目的:
- 评估印第安患者中伊诺图祖马布奥佐加米辛的疗效和安全性,这些患者患有复发性耐火B细胞急性淋巴细胞白血病.
- 为了评估可测量的残留疾病 (MRD) 的负面性和完全缓解 (CR) 的率,通过INO疗法实现.
主要方法:
- 一项回顾性研究评估了12名RR-ALL患者 (3名儿童),这些患者接受了 inotuzumab ozogamicin 治疗.
- 患者接受了InO作为预先治疗,持续的MRD阳性或活跃的疾病,并分析了治疗周期和结果.
主要成果:
- 12名患者中有10名 (83%) 实现了MRD阴性完全缓解 (CR).
- 七名患者在仅服用一轮InO后,获得了MRD阴性.
- 所有MRD阳性患者转化为MRD阴性缓解,其中4人进行了全原骨髓移植.
结论:
- 在B细胞急性淋巴细胞白血病中,伊诺图祖马布 (inotuzumab ozogamicin) 在诱导深度缓解方面表现出显著的疗效.
- 该药物即使在多次复发患者和持久性MRD患者中也有效.
- 需要进一步的前性研究来证实印度人口中的这些发现.
相关概念视频
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K